Cheney J G Drew
Overview
Explore the profile of Cheney J G Drew including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ioakeimidis V, Busse M, Drew C, Pallmann P, Watson G, Jones D, et al.
BMJ Open
. 2024 Aug;
14(7):e082161.
PMID: 39089721
Introduction: Huntington's disease (HD) is an inherited neurodegenerative disease causing progressive cognitive and motor decline, largely due to basal ganglia (BG) atrophy. Rhythmic training offers promise as therapy to counteract...
2.
Lane E, Drew C, Lelos M
Int Rev Neurobiol
. 2022 Nov;
166:xi-xii.
PMID: 36424098
No abstract available.
3.
Drew C, Busse M
Int Rev Neurobiol
. 2022 Nov;
166:235-279.
PMID: 36424094
The recent advances in the development of potentially disease modifying cell and gene therapies for neurodegenerative disease has resulted in the production of a number of promising novel therapies which...
4.
Quinn L, Playle R, Drew C, Taiyari K, Williams-Thomas R, Muratori L, et al.
Parkinsonism Relat Disord
. 2022 Jul;
101:75-89.
PMID: 35809488
Introduction: While physical activity (PA) is recognized as important in Huntington's disease (HD) disease management, there has been no long-term evaluation undertaken. We aimed to evaluate the feasibility of a...
5.
Drew C, Sharouf F, Randell E, Brookes-Howell L, Smallman K, Sewell B, et al.
Brain Commun
. 2021 Feb;
3(1):fcaa230.
PMID: 33543141
Huntington's disease is a progressive neurodegenerative disorder characterized by motor, cognitive and psychiatric symptoms. Currently, no disease-modifying therapies are available to slow or halt disease progression. Huntington's disease is characterized...
6.
Yhnell E, Furby H, Lowe R, Brookes-Howell L, Drew C, Playle R, et al.
Pilot Feasibility Stud
. 2020 Jun;
6:88.
PMID: 32577299
Background: Huntington's disease (HD) is associated with a range of cognitive deficits including problems with executive function. In the absence of a disease modifying treatment, cognitive training has been proposed...
7.
Drew C, Postans M, Petralia C, McNamara R, Pallmann P, Gillespie D, et al.
Pilot Feasibility Stud
. 2019 Jul;
5:87.
PMID: 31321071
Background: People with temporal lobe epilepsy (TLE) report significant problems with learning and memory. There are no effective therapies for combatting these problems in people with TLE, resulting in an...
8.
Drew C, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, et al.
Phys Ther
. 2019 May;
99(9):1201-1210.
PMID: 31101920
Background: Exercise is emerging as an important aspect in the management of disease-related symptoms and functional decline in people with Huntington disease (HD). Long-term evaluation of physical activity and exercise...
9.
Yhnell E, Furby H, Breen R, Brookes-Howell L, Drew C, Playle R, et al.
Pilot Feasibility Stud
. 2018 Feb;
4:45.
PMID: 29445514
Background: Cognitive impairments, especially deficits of executive function, have been well documented as a core and early feature in Huntington's disease (HD). Cognitive impairments represent considerable burden and can be...
10.
Drew C, Poile V, Trubey R, Watson G, Kelson M, Townson J, et al.
Trials
. 2016 Nov;
17(1):551.
PMID: 27855710
Background: Trials of complex interventions are associated with high costs and burdens in terms of paperwork, management, data collection, validation, and intervention fidelity assessment occurring across multiple sites. Traditional data...